AGILE (Early Phase Platform Trial for COVID-19)
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Covid19
In brief
The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be based on pre-clinical data, evidence in the clinical setting and GMP capabilities.
Key facts
- Study ID
- NCT04746183
- Run by
- University of Liverpool
- People needed
- 600
- Starts
- 2020-07-03
- Expected to finish
- 2027-03-31
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Royal Free Hospital — London, United Kingdom (enrolling)
- Manchester University NHS Foundation Trust — Manchester, United Kingdom (enrolling)
- University Hospital Southampton NHS Foundation Trust — Southampton, United Kingdom (enrolling)
- Liverpool University Hospitals NHS Foundation Trust — Liverpool, United Kingdom (enrolling)
- Kings College Hospital NHS Foundation Trust — London, United Kingdom
- Ezintsha — Johannesburg, South Africa
- Desmond Tutu Health Foundation — Cape Town, South Africa
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.